Innovative Models in the Rehabilitation of the Elderly With Stroke Through Technological Innovation

Assistive Robotic in the Elderly: Innovative Models in the Rehabilitation of the Elderly With Stroke Through Technological Innovation

The final goal of the present study is to propose a new approach and an innovative therapeutic plan in the post-stroke rehabilitation of elderly patients, focused on the use of robotic device, in order to obtain the beneficial effects of this treatment.

Study Overview

Detailed Description

Stroke is a leading cause of disability, injury, and death in elderly people and represents a major public health problem with substantial medical and economic consequences. The incidence of stroke rapidly increases with age, doubling for each decade after age 55 years. Gait impairment is one of the most important problems after stroke and improve walking function is often a key component of any rehabilitation program. To achieve this goal, robotic gait trainer seems to be promising. In fact, some studies underline the efficacy of robotic gait training based on end-effector technology, for different diseases, in particular in stroke patients. In this randomized controlled trial, we verify the efficacy of the robotic treatment in terms of improving the gait and reducing the risk of falling and its long-term effects.

In this single blind randomized controlled trial the investigators will include 150 elderly subacute stroke patients divided in two groups to receive a traditional rehabilitation program or a robotic rehabilitation using G-EO system, an end-effector device for the gait rehabilitation, in addition to the traditional therapy. A 20 treatment sessions will be conducted, divided into 3 training sessions per week, for 7 weeks. The control group will perform traditional therapy sessions lasting 50 minutes. The technological intervention group, using G-EO system, will carry out 30 minutes of traditional therapy and 20 minutes of treatment with a robotic system. The primary outcome of the study is the evaluation of the falling risk. Secondary outcomes are the assessment of the gait improvements and the fear of falling. Further evaluations, such as length and asymmetry of the step, walking and functional status, acceptance of the technology, will be carried.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Ancona, Italy, 60131
        • Recruiting
        • IRCCS INRCA Hospital
        • Contact:
        • Principal Investigator:
          • Giovanni R Riccardi, MD
      • Fermo, Italy
        • Not yet recruiting
        • IRCCS INRCA Hospital
        • Contact:
        • Principal Investigator:
          • Pietro Scendoni, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Capacity to consent
  • Ischemic or hemorrhagic stroke within 3 months to the recruitment, proven by computerized axial tomography or nuclear magnetic resonance
  • Functional Ambulation Category (FAC) score ≤ 2
  • Ranking scale score ≤ 3
  • Complete communication and comprehension skills, assessed during the objective examination
  • Ability to stand upright, supported or unsupported, for 1 minute

Exclusion Criteria:

  • Concomitant participation in other studies
  • Severe hypertonus of the hip, knee, ankle of the paretic leg with a modified Ashworth scale score ≥3
  • Severe hip, knee or ankle contracture or orthopedic problem affecting ambulation that would preclude passive range of motion of the paretic leg
  • Deep vein thrombosis of the lower limbs
  • Other cognitive, motor and sensory deficits that negatively condition robotic training
  • Treatment of spasticity of the lower limb within 3 months to the start of the study or during the study
  • Lack of written informed consent
  • Clinical dementia rating (CDR) score ≥ 3
  • Severe systemic diseases with life expectancy < 1 year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: technological intervention arm
Twenty technological treatment sessions divided into 3 training sessions per week for 7 weeks.
Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training (G-EO system, Reha Technology, Switzerland), an end-effector technology that simulates floor walking and stairs climbing (up and down)
Active Comparator: Control arm
Twenty traditional treatment sessions divided into 3 training sessions per week for 7 weeks.
Each session will include 50 minutes of traditional physical rehabilitation therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
difference in falling risk between experimental arm and control arm
Time Frame: before treatment, at the end of rehabilitation sessions and 6 months, 12 months and 24 months after intervention
falling risk will be evaluated by the Tinetti performance oriented mobility assessment (POMA). Balance section of Tinetti Performance Oriented Mobility Assessment (Tinetti Performance Oriented Mobility Assessment has two subscales, Balance and Gait section.) Balance section has 9 items. Each item can be scored in a 3 point ordinal scale (0-2). "0" indicates the lowest level of function and "2" the highest level of function. Total Score = 16. Total score is obtained by adding the individual scores.
before treatment, at the end of rehabilitation sessions and 6 months, 12 months and 24 months after intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
difference in gait performance between experimental arm and control arm
Time Frame: before treatment, at the end of rehabilitation sessions and 6 months, 12 months and 24 months after intervention
gait performance will be evaluated by the walking speed evaluated by instrumental gait analysis
before treatment, at the end of rehabilitation sessions and 6 months, 12 months and 24 months after intervention
difference in fear of falling between experimental arm and control arm
Time Frame: before treatment, at the end of rehabilitation sessions and 6 months, 12 months and 24 months after intervention
fear of falling will be evaluated by the Falls Efficacy Scale - International (FES-I). Higher scores represent greater the fear of falling (ranging from 16 to 64)
before treatment, at the end of rehabilitation sessions and 6 months, 12 months and 24 months after intervention
difference in quality of life between experimental arm and control arm: SF-12 health survey
Time Frame: before treatment, at the end of rehabilitation sessions and 6 months, 12 months and 24 months after intervention
Quality of life will be measured using the Hausa SF-12 Health Survey (SF-12-H). The questionnaire consists of 12 items questioned weighted and summed to provide physical and mental health scores (PCS and MCS). The two composite scores are computed using the scores on twelve questions that range from 0 to 100, with higher score indicating better health
before treatment, at the end of rehabilitation sessions and 6 months, 12 months and 24 months after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 15, 2021

Primary Completion (Estimated)

March 30, 2024

Study Completion (Estimated)

March 30, 2024

Study Registration Dates

First Submitted

September 10, 2019

First Submitted That Met QC Criteria

September 11, 2019

First Posted (Actual)

September 12, 2019

Study Record Updates

Last Update Posted (Actual)

October 23, 2023

Last Update Submitted That Met QC Criteria

October 20, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Technological intervention arm

Subscribe